Financials Coya Therapeutics, Inc.

Equities

COYA

US22407B1089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
7.91 ^USD	-2.94%		-9.39%	+6.75%

05-20	Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation	MT
05-17	Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation	CI

Valuation

Fiscal Period: December	2022	2023	2024	2025	2026
Capitalization ¹	12.27	106.7	120.3	-	-
Enterprise Value (EV) ¹	12.27	106.7	120.3	120.3	120.3
P/E ratio	-1 x	-9.38 x	-6.7 x	-5.15 x	-
Yield	-	-	-	-	-
Capitalization / Revenue	-	17.8 x	23.5 x	17.8 x	4.01 x
EV / Revenue	-	17.8 x	23.5 x	17.8 x	4.01 x
EV / EBITDA	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Price to Book	-	-	-	-	-
Nbr of stocks (in thousands)	2,590	14,401	15,205	-	-
Reference price ²	4.738	7.410	7.910	7.910	7.910
Announcement Date	23-03-29	24-03-19	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net sales ¹	-	-	6	5.114	6.75	30
EBITDA	-	-	-	-	-	-
EBIT ¹	-	-9.812	-7.903	-16.97	-28.26	-
Operating Margin	-	-	-131.72%	-331.81%	-418.7%	-
Earnings before Tax (EBT) ¹	-	-12.24	-7.264	-16.22	-28.04	-
Net income ¹	-4.892	-12.24	-7.988	-16.22	-28.04	-
Net margin	-	-	-133.13%	-317.3%	-415.42%	-
EPS ²	-0.3300	-4.730	-0.7900	-1.180	-1.535	-
Free Cash Flow	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-
Announcement Date	22-11-18	23-03-29	24-03-19	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2
Net sales ¹	-	-	-	6	-	4.2	4.2	-	0.9	0.9
EBITDA	-	-	-	-	-	-	-	-	-	-
EBIT ¹	-2.9	-2.904	-3.564	1.815	-	-1.778	-2.428	-7.278	-	-
Operating Margin	-	-	-	30.25%	-	-42.33%	-57.81%	-	-	-
Earnings before Tax (EBT) ¹	-	-3.095	-3.422	1.99	-	-1.67	-2.324	-7.179	-	-
Net income ¹	-2.736	-3.095	-3.422	1.266	-5.052	-1.67	-2.324	-7.179	-8.1	0.95
Net margin	-	-	-	21.1%	-	-39.76%	-55.33%	-	-900%	105.56%
EPS ²	-0.2800	-0.3100	-0.3400	0.1500	-0.3500	-0.1100	-0.1600	-0.4900	-0.4450	-0.1350
Dividend per Share	-	-	-	-	-	-	-	-	-	-
Announcement Date	23-05-10	23-08-08	23-11-08	24-03-19	24-05-09	-	-	-	-	-

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-
ROE (net income / shareholders' equity)	-	-	-	-	-	-
ROA (Net income/ Total Assets)	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-
Book Value Per Share	-	-	-	-	-	-
Cash Flow per Share	-	-	-	-	-	-
Capex	-	-	-	-	-	-
Capex / Sales	-	-	-	-	-	-
Announcement Date	22-11-18	23-03-29	24-03-19	-	-	-

¹USD in Million

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Coya Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.91 USD

Average target price

14.5 USD

Spread / Average Target

+83.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COYA THERAPEUTICS, INC.	+6.75%	120M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research